Telix Pharmaceuticals Limited, an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today announced the establishment Telix Pharmaceuticals (Japan) Ltd and appointment of the first two members of the Japanese leadership team.
Telix Japan is wholly owned operating subsidiary of Telix Pharmaceuticals Limited. The purpose of the subsidiary is to support the company’s Japanese clinical and radiopharmaceutical manufacturing activities and to establish a commercial footprint in the Japan, an important market for Telix’s products.
To lead the Telix Japan activities, Dr. Shintaro Nishimura and Dr. Takeshi Oka have been appointed as president and chief operating officer, and chief medical officer (Japan), respectively.
“Japan is one of the most important prospective markets for Telix’s products and our activities in Japan covers a range of manufacturing and collaboration activities with leading Japanese clinical sites and biopharmaceutical companies,” Telix co-founder and CEO Dr. Christian Behrenbruch said. “The Japanese radiopharmaceutical landscape is evolving rapidly, and we are pleased to have been able to hire two extremely high-caliber executives to lead our development and commercial activity.”
(Source: Telix Pharmaceuticals Limited)
